In high-throughput poultry and swine operations, drinking-water medication is selected when mass administration must be achieved without animal-by-animal handling; sulphadimidine sodium is dry-blended into water-soluble oral powders at active concentrations of 10–30% w/w to allow rapid reconstitution in farm water systems. The sodium salt is used rather than the free base because the base form exhibits pH-dependent solubility below 2 mg/mL in neutral aqueous media, while the sodium salt forms clear stock solutions at 20–25°C up to 250 mg/mL; this difference determines premix design and final in-use dilution. Compliance is governed by the current European Pharmacopoeia monograph for sulfadimidine sodium, with residual solvent limits evaluated under ICH Q3C(R8)/VICH GL18(R2) and elemental impurities screened under ICH Q3D(R2); finished non-sterile oral powders are additionally tested for microbial quality according to Ph. Eur. 5.1.4 and for uniformity of mass under Ph. Eur. 2.9.5. Downstream production at veterinary pharmaceutical CMO facilities typically involves a 1000 L twin-shell blender operated at 50–60% nominal volumetric capacity, because oversizing reduces shear and yields carbohydrate-based diluent segregation; a pre-blend of sulphadimidine sodium, anhydrous glucose or lactose monohydrate, and sodium citrate buffer is passed through a 1.0 mm sieve and blended for 15–25 minutes, with in-process relative humidity held below 40% RH to prevent hygroscopic bridging on blender surfaces and filling augers. The final products are sealed aluminium-foil pouches of 100 g, 500 g, and 1 kg, termed water-soluble powder for oral solution; the medicated stock solution must be prepared with softened or deionised water because hard water containing carbonate hardness above 200 ppm CaCO₃ can reduce solubility and cause precipitation in dosing lines.

What Limits Terminal Sterilisation of Sulphadimidine Sodium Injection in Multi-Dose Vials?

The aqueous solubility of sulphadimidine sodium permits a 33.3% w/v (equivalent to 333 mg/mL) injectable solution, but the formulation boundary is not solubility alone: the sulphonamide ring undergoes oxidative discoloration and pH-dependent precipitation when alkaline solutions are exposed to atmospheric oxygen or when pH falls below approximately 8.5. Industrial compounding therefore proceeds under nitrogen overlay in closed stainless-steel vessels, with the API dissolved in water for injection at 60–70°C and the pH adjusted to 9.0–10.5 using 0.1 N sodium hydroxide; an antioxidant such as sodium metabisulphite at 0.1% w/v is added to control oxidation, and disodium edetate at 0.01% w/v chelates trace metal ions that accelerate degradation. Regulatory compliance for the injectable form is anchored to Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 and USP <85> for bacterial endotoxins, USP <788> for particulate matter, and ICH Q3C(R8) for residual solvents; sterile manufacture follows 21 CFR 211.110 in-process control and 21 CFR 211.166 stability commitments. Terminal sterilisation is deliberately avoided in many sites because published data for specific autoclave cycles on sulphadimidine sodium are limited and because the pH range required for dissolution conflicts with thermal stability; typical operations use two-stage sterilising filtration through 0.22 µm PVDF or PES membrane filters and aseptic filling into Type I borosilicate glass vials. The final presentations are 100 mL and 250 mL multi-dose vials sealed with bromobutyl rubber closures, intended for intramuscular or subcutaneous administration after dilution or direct injection as authorised by the veterinary SPC.

Free-base sulphadimidine is selected for direct compression of ruminant boluses because the sodium salt is hygroscopic and produces tablets with high friability and capping at industrial compression speeds, whereas the base form can be dry-granulated into high-density units containing 1–5 g active per bolus. The formulation ratio is typically 80–90% w/w sulphadimidine base, 3–5% w/w povidone K30 as dry binder, 2–4% w/w crospovidone as disintegrant, and 0.5–1.0% w/w magnesium stearate as lubricant; all percentages are expressed relative to total core weight, and the active content is adjusted between 1 g and 5 g according to target species body weight. Downstream processing uses a roller compactor operating at 15–25 kN/cm roll pressure, followed by dry milling to granules with D50 between 200 µm and 600 µm; the resulting granules are compressed on a rotary tablet press at 20–40 rpm and 15–25 kN main compression force to achieve tablet hardness 80–120 N and friability not exceeding 1.0% under Ph. Eur. 2.9.7. Disintegration is controlled by Ph. Eur. 2.9.1 and dissolution by USP <711> in 0.1 M hydrochloric acid; content uniformity is verified under Ph. Eur. 2.9.40. The terminal finished products are 5 g and 10 g oral boluses packed in PVC/aluminium blisters or HDPE jars, intended for oral dosing in calves, sheep, and goats under veterinary supervision.

Medicated Feed Granule Homogeneity and Cross-Contamination Control in Multi-Species Mills

When sulphadimidine base is incorporated into medicated feed granules, the unit operation priority shifts from dissolution performance to dry-solids homogeneity and carryover suppression in multi-species mills. The premix is manufactured at 10–25% w/w active base on a calcium carbonate or wheat flour carrier, then blended into final feed at inclusion rates determined by the veterinary prescription; common final feed active concentrations lie between 200 g/tonne and 500 g/tonne for short-course antimicrobial medication, but the exact target is derived from the approved SPC. Granulation is performed in a high-shear mixer with impeller tip speed 8–12 m/s, followed by fluid-bed drying at inlet air temperature 60–65°C until moisture content is below 1.5% w/w; the dried granules are size-selected through a 1.6 mm sieve to prevent segregation during pneumatic conveying. Compliance requires batch homogeneity testing by Ph. Eur. 2.9.40 or equivalent, with a coefficient of variation of active content not exceeding 5.0% across 10 sampling points; cleaning validation for production equipment follows 21 CFR 211.67, and residual solvent/elemental impurity specifications are applied under ICH Q3C(R8) and ICH Q3D(R2). Terminal finished products are 10% and 25% w/w medicated premixes in 20 kg multi-wall paper bags with inner polyethylene liners, or bulk tote bins for integrated feed mills.

When Sulphadimidine Sodium Is Used in High-Alkalinity Oral Drench Concentrates for Neonatal Ruminants

In neonatal calf and lamb rearing streams, oral drench concentrates are compounded with sulphadimidine sodium at 20–40% w/v to provide an aqueous, ready-to-dose liquid for oesophageal administration. The alkaline pH window between 10.0 and 11.0 is maintained with sodium hydroxide or monoethanolamine to keep the sodium salt in solution; below approximately 9.0, free-base precipitation can occur, and above 11.5, mucosal irritation and chemical degradation increase. Production is conducted in jacketed stainless vessels at 20–25°C, with nitrogen blanketing and 0.1% w/v sodium metabisulphite to limit oxidation; the solution is passed through a 0.45 µm clarifying filter and then filled into amber HDPE or PET bottles of 500 mL and 1 L. Compliance for this non-sterile oral liquid includes Ph. Eur. 5.1.4 for microbial quality, ICH Q3C(R8) for residual solvents, and 21 CFR 211.110 for in-process control of pH, density, and active content by HPLC. The terminal finished products are aqueous oral drench concentrates for calves, lambs, and goat kids, dispensed with calibrated dosing guns.

Low-Dose Compounded Capsule Filling for Individual Animal Dosage Regimens

Compounded oral capsules containing sulphadimidine base are prepared for individual animal dosing when tablet strengths are unsuitable or when veterinary hospital pharmacies require unit-dose flexibility. The formulation combines base-form API at 250 mg or 500 mg per capsule with lactose monohydrate as filler, croscarmellose sodium at 2% w/w as disintegrant, and magnesium stearate at 0.5% w/w as lubricant; fill weight is typically 300–600 mg for size 0 or size 1 hard gelatin capsules. Processing proceeds by geometric dilution in a mortar or low-shear planetary mixer, followed by semi-automatic capsule filling with intermittent weight verification; content uniformity is assessed under Ph. Eur. 2.9.40, and disintegration under Ph. Eur. 2.9.1. Published data for this specific configuration are limited, so formulation development batches should include dissolution testing under USP <711> at pH 1.2 and pH 6.8 to confirm batch-to-batch uniformity. The terminal finished products are hard gelatin or HPMC capsules in 100-count or 500-count HDPE bottles, labelled for veterinary prescription use only.